Jump Financial LLC Has $5.48 Million Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP)

Jump Financial LLC raised its stake in CRISPR Therapeutics AG (NASDAQ:CRSP) by 174.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 139,280 shares of the company’s stock after acquiring an additional 88,448 shares during the quarter. Jump Financial LLC owned about 0.16% of CRISPR Therapeutics worth $5,482,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of the stock. ARK Investment Management LLC boosted its holdings in CRISPR Therapeutics by 19.7% in the fourth quarter. ARK Investment Management LLC now owns 8,973,064 shares of the company’s stock valued at $353,180,000 after acquiring an additional 1,474,439 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of CRISPR Therapeutics by 0.6% in the 4th quarter. Vanguard Group Inc. now owns 1,735,998 shares of the company’s stock valued at $68,329,000 after purchasing an additional 10,579 shares during the last quarter. Geode Capital Management LLC grew its position in shares of CRISPR Therapeutics by 3.6% during the 3rd quarter. Geode Capital Management LLC now owns 1,008,214 shares of the company’s stock worth $47,383,000 after buying an additional 35,196 shares during the period. Norges Bank acquired a new position in CRISPR Therapeutics in the fourth quarter valued at approximately $17,458,000. Finally, Contrarius Group Holdings Ltd bought a new position in CRISPR Therapeutics in the fourth quarter valued at approximately $14,516,000. 69.20% of the stock is owned by institutional investors.

CRISPR Therapeutics Trading Down 3.0 %

CRISPR Therapeutics stock opened at $37.78 on Thursday. The company has a fifty day simple moving average of $41.00 and a 200 day simple moving average of $43.87. CRISPR Therapeutics AG has a 1-year low of $30.04 and a 1-year high of $67.88. The company has a market cap of $3.24 billion, a P/E ratio of -8.65 and a beta of 1.85.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. On average, equities research analysts forecast that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

Insider Transactions at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 18,360 shares of the business’s stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total transaction of $1,013,472.00. Following the transaction, the chief executive officer now directly owns 171,613 shares in the company, valued at $9,473,037.60. The trade was a 9.66 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Julianne Bruno sold 1,198 shares of the firm’s stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total transaction of $50,819.16. Following the completion of the sale, the chief operating officer now owns 8,263 shares of the company’s stock, valued at $350,516.46. This trade represents a 12.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 32,381 shares of company stock worth $1,608,243 in the last 90 days. Corporate insiders own 4.10% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. Morgan Stanley increased their price target on CRISPR Therapeutics from $30.00 to $32.00 and gave the company an “underweight” rating in a research note on Friday, February 14th. HC Wainwright restated a “buy” rating and set a $65.00 target price on shares of CRISPR Therapeutics in a report on Thursday, February 13th. Stifel Nicolaus decreased their target price on CRISPR Therapeutics from $53.00 to $49.00 and set a “hold” rating for the company in a research report on Thursday, February 13th. Truist Financial lifted their price objective on shares of CRISPR Therapeutics from $100.00 to $120.00 and gave the stock a “buy” rating in a research note on Wednesday, February 12th. Finally, Citigroup lowered their target price on shares of CRISPR Therapeutics from $89.00 to $82.00 and set a “buy” rating for the company in a research note on Tuesday, February 18th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat.com, CRISPR Therapeutics presently has an average rating of “Hold” and a consensus price target of $73.11.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.